Breaking the impasse: time for decisive action?
D000911:Antibodies, Monoclonal / Q000191:economics / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab; D017046:Cost Savings; D004345:Drug Industry / Q000191:economics*; D004469:Economics, Hospital; D004470:Economics, Medical; D006801:Humans; D007356:Insurance, Pharmaceutical Services / Q000191:economics*; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000068818:Cetuximab